Astria Therapeutics at Citizens JMP: Advancing HAE Treatments

On Wednesday, 07 May 2025, Astria Therapeutics (NASDAQ:ATXS) presented at The Citizens JMP Life Sciences Conference 2025, highlighting their strategic focus on developing innovative treatments for hereditary angioedema (HAE) and allergic diseases. The discussion centered on their promising drug candidates, Nivenabart and STAR-310, with an optimistic outlook on their potential market impact. However, challenges in a competitive landscape were acknowledged.

Key Takeaways

• Astria Therapeutics is advancing Nivenabart, showing over 90% attack reduction in HAE patients.
• The company is financially robust, with cash reserves expected to last through mid-2027.
• STAR-310 is in Phase 1a trials, targeting allergic and immunologic diseases with anticipated data in Q3.
• Astria aims for Nivenabart to become a market leader in the $5.4 billion HAE market by 2030.

Financial Results

• Astria reports a strong cash position, ensuring financial stability through mid-2027.
• This financial runway supports key milestones, including Nivenabart’s Phase 3 program.

Operational Updates

• Nivenabart (HAE)

- Phase 1b trials showed significant efficacy with quarterly or bi-annual dosing.

- The Phase 3 trial is underway, designed for US, Europe, and Japan registration, with top-line data expected in early 2027.

- Upcoming Alpha Solar long-term extension data will focus on safety and efficacy.

• STAR-310 (OX40 antagonist)

- Currently in Phase 1a trials, with data expected in Q3, focusing on safety and efficacy.

Future Outlook

• Nivenabart (HAE)

- Astria is positioning Nivenabart as a leading treatment in the growing HAE market.

• Upcoming Milestones

- Mid-year: Alpha Solar data on Nivenabart.

- Q3: Phase 1a data for STAR-310.

- Early 2027: Nivenabart Phase 3 top-line data.

Q&A Highlights

• Nivenabart Trial Design

- The Phase 3 trial includes both quarterly and bi-annual dosing regimens, with a focus on reducing attack rates.

• STAR-310 Differentiation

- Engineered to avoid safety issues seen in other OX40 programs, aiming for better efficacy in atopic dermatitis.

Astria Therapeutics is poised for growth with its innovative pipeline and strong financials. For more details, readers can refer to the full transcript below.

Full transcript - The Citizens JMP Life Sciences Conference 2025:

John Wallabin, Senior Analyst, Citizens Life Science Conference: Morning, everybody, and welcome to day one of the Citizens Life Science Conference. My name is John Wallabin, senior analyst here. We’re pleased to have Astria Therapeutics and CEO, Jill Millney, joining us today. Astria is a company we launched coverage on, I think, earlier this year in January. We’ve been covering the hereditary angioedema space for quite some time, and I think this is one of the more compelling pipeline candidates out there.

So Jill, thanks so much again for joining us.

Jill Millney, CEO, Astria Therapeutics: My pleasure. Thanks for having us.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And I mentioned HAE, but maybe if you could talk a little bit about Astra broadly, your overall strategy and mission.

Jill Millney, CEO, Astria Therapeutics: Yeah, for sure. So at Astria, our focus is to develop first choice products for people living with allergic and immunologic diseases. By first choice, we mean that patients and physicians would choose our products first based on the competitive efficacy profile, favorable safety tolerability, and low treatment burden. And I think we have that with both of the programs in our pipeline. So our lead program is Nivenabart, which we’re developing as a preventative therapy for a disease called hereditary angioedema or HAE.

Nivenabart is a monoclonal antibody inhibitor of an enzyme called plasma calacrine and this enzyme is clinically commercially validated for the treatment of hereditary angioedema. What excites us about Nivenabart and its potential in HAE is the efficacy profile we’ve demonstrated in our phase 1btwo trial with Nivenabart that showed a greater than ninety percent attack rate reduction in patients. And that attack rate reduction was with dosing once every three months. And also we showed it with dosing once every six months. So a pretty compelling profile that we think will really change the way people live with this disease, hereditary angioedema.

Our second program is STAR310. That is a monoclonal antibody antagonist of the OX40 receptor. OX40 has become an incredibly interesting pathway. It is a mediator of T cell biology and is implicated in a number of T cell mediated diseases. It’s a mechanism that’s been validated in atopic dermatitis.

And also there’s been some data this year so far from some of the other programs in the space showing efficacy in diseases in subpopulations in asthma, in HS, and in alopecia. So really interesting mechanism. So STARR310 for us, we’re in a phase 1a healthy subject trial. And we expect to report initial results from that Q3 this year, which we believe will read on the differentiation of STARR310 among the OX40 space.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Well, there’s a lot we like about the story and the strategy. We got clinically validated targets, known development paths, well established commercial opportunities, and differentiated profiles. Like you check those four boxes, there are a lot of buzzwords, but that usually means you’re doing something right and we’re getting rid of a lot of risk out there. But when we talk about well established commercial opportunities, hereditary angioedema is one of the best poster childs for rare disease drug development, building a market, finding patients, having good revenues. It’s gotten really competitive.

Can you talk a little bit about the landscape in the prophylactic setting? How it’s changed over the years? You know, what works today? And then you mentioned the Venabarts, you know, longer dosing. But how do you see this fitting in?

How’s the landscape evolve?

Jill Millney, CEO, Astria Therapeutics: Yeah, absolutely. So as far as, you know, rare diseases go, hereditary angioedema is pretty unique in that it is a relatively large patient population as far as rare diseases go and as you said the landscape has evolved incredibly. You know a little over twenty years ago there were no mechanism based therapies for the treatment of HAE. That has changed and, what’s great is patients now have some options and I think what we hope to do with Nivenabart is to bring, what we think could be a first choice option to patients. But the market itself is large and it is growing.

We anticipate or expect the market to be about $5,400,000,000 by 02/1930. That growth is expected to come from earlier diagnosis Now that there are therapies out there, patients are being diagnosed earlier. We also think greater utilization of preventative therapies is going to expand the market size and then also geographic expansion. So those three things contribute to the market growth that we expect over the next few years.

It is a competitive space, but what gives us confidence in the Venobar to stand out among the other players in the space is, you know, it’s based on a trusted mechanism. It’s based on a trusted modality. The efficacy profile that we’ve shown in our phase one b two trial in patients this greater than ninety percent attack rate reduction and swelling attacks are the hallmark of this disease HAE. And the fact that the profile that we’ve built into this program to dose as infrequently as every three months or every six months depending on the patient needs. We think that really sets Nivenabart up to be a highly competitive agent in this space.

Quite frankly, our vision for it is to become the market leading product in HAE.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And the other thing that I like is that we’ve seen evidence of patients’ willingness to switch. Some products are sticky in a small percentage of patients, but when something new comes to market, patients are willing to try it because the other thing about the drugs that are out there, and this is true for every drug, it doesn’t work for everybody. So when something comes out that may be safer, more tolerable, easier to take, patients are willing to try it in the hereditary angioedema space where patients are well educated, motivated, and connected, they’re pretty well aware of what’s going on in development, right?

Jill Millney, CEO, Astria Therapeutics: Absolutely, absolutely. And I think what we’ve seen in the space is that willingness to switch for things that are better. And as the landscape, the competitive landscape and more therapies have come to market, we see patients switching for that better efficacy or better safety and tolerability, a better fit with their lifestyle. And we hope we kind of hit all three of those with Invenibart.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And you mentioned your phase one data earlier, but can you dig into a little bit about what you showed?

Jill Millney, CEO, Astria Therapeutics: Sure. Yeah, so the phase 1btwo trial, we read the final results from the original 16 patients in December of last year. And what that data showed was that navenibart over a six month period given either once or twice, so that Q3 month or Q6 month dosing, led to a greater than ninety percent reduction in attack rate, led to a greater than ninety percent reduction in moderate to severe attacks, led to a greater than ninety percent reduction in the use of rescue medications, showed a favorable safety tolerability profile, and supported this concept that we have a profile and that could support robust efficacy with very infrequent dosing.

John Wallabin, Senior Analyst, Citizens Life Science Conference: How does that compare to what’s available today to patients?

Jill Millney, CEO, Astria Therapeutics: Yeah, I think it compares quite favorably to what is available today for patients and with what we see coming to the market in the coming months and year in terms of the efficacy profile. The market leading product is TEXYRO which is also a monoclonal antibody inhibitor of plasma calacrine. What we expect for Nivenabart is to match or beat TEXYRO in terms of efficacy to improve upon the tolerability of the injection and to dose much less frequently. Taxiro is currently dosed in most patients every two weeks and you can imagine fitting into the lifestyle if you’re traveling, do you want to take a medication that’s an injection and have to keep it cold while you’re away for a few weeks? So nivenabart really will change how people think about living with this disease.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And can you talk a little bit about, if we’re being critical and we’ve heard this argument, you’ve a small number of patients, open label trial, no control, and you’re going right to phase three, what should give people confidence that the data were for real?

Jill Millney, CEO, Astria Therapeutics: Yeah, I think HAE is a pretty unique disease in the sense that these attacks are incredibly objective. Like a patient has an attack, it’s a swelling attack. When a patient swells you know that they’re having an attack. And these attacks are adjudicated by the physicians that are overseeing these patients in the trial. And so that gives us good confidence that what we’re seeing is real.

And of course this is a validated mechanism, validated modality, so we have a good indication you inhibit this enzyme, you’re going to have a read through on lowering the attack rate in these patients.

John Wallabin, Senior Analyst, Citizens Life Science Conference: We kind of glossed over this, but how are you able to kind of get a longer duration of action for the monoclonal?

Jill Millney, CEO, Astria Therapeutics: Yeah, so our antibody was engineered in the Fc region. What we introduced was a sequence called YTE, So these three amino acid changes that lead to an extended half life of the antibody. And that has led in our phase 1a healthy subject trial, the half life was about ninety days for the antibody. So it allows for this very infrequent dosing.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And we’re going get an update from your open label extension, I believe, year. Can you talk a little bit about what data you’ll be showing then? Because when we’re talking about smaller patients, when we have more follow-up, that obviously gives us more confidence. But what should you guys be showing us in a few months here?

Jill Millney, CEO, Astria Therapeutics: Yeah, so we expect to share data from our alpha solar trial. This is the long term extension from our phase 1btwo alpha star trial. And so that’ll be mid year. What we that trial was designed of course to show long term safety, but importantly it also allows us to look at a durability of the efficacy effect. In the patients all of the patients from the that original 16 chose to enroll in the alpha solver so we took that as a good sign that they like what they’re seeing in nivenabart for themselves.

So we’ll show efficacy data as well as again, looking at safety tolerability. Our expectation would be this data would be very much in line with what we showed with the alpha star phase 1btwo trial.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And does that mean eighty percent attack reduction or do you want to be in that ninety percent? Because this is a threshold disease. If you’re mopping up plasma kallikrein, it’s hard to have an attack. But if you’re following people for years, they’re going to have a breakthrough attack at some point. So how do we think about that balance between having enough protection but also the patients are going to have breakthrough attacks, it happens.

Jill Millney, CEO, Astria Therapeutics: Yeah, great question. So our target profile as we thought about Nivenabart in our design was to target that eighty to ninety percent attack rate reduction. And so that’s what we hope to be able to achieve not only in this in the data that we’ll share with Alpha Solar, the long term extension, but ultimately what we hope to achieve in the phase three as well.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And are you seeing if someone does have an attack on therapy, is it less severe? Or is there a way to monitor that pre and post treatment? Every attack I used to have was I’d be down for two days versus oh now I just have some swelling in my hands. Have you guys looked at severity of attacks on drug?

Jill Millney, CEO, Astria Therapeutics: Absolutely. And so what we’ve been able to show is that there is a significant reduction in the severity of attacks following treatment with Nivenabart. So in the phase 1btwo trial we showed a greater than, I think it was like a ninety three to ninety five percent reduction in moderate to severe attacks. So attacks became mild if a patient was going to have them. So that’s a huge improvement as well.

So we can reduce attacks by eighty to ninety percent overall, but also the severity of an attack if it should occur. That’s, we think, you know, really a game changer for patients.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And the other, you know, I think really positive development that I’m not sure if people have appreciated quite yet is your phase three trial and its design. Can you talk a little bit about what happened with you guys and FDA and then overview of that trial design?

Jill Millney, CEO, Astria Therapeutics: Yeah, we’re really thrilled with the design and where we ended up with the design. So we’re running the phase three. A single phase three, we’re able to test both the every three month and the every six month regimens. And that’s with a six month treatment period. So the primary endpoint of our pivotal is after six months of dosing.

And so that design enabled us to run a single phase three to support both of those dose regimens, which is I think great for patients and great for us as well. And this trial is being run globally and we expect that this trial should support registration not only in The US but in Europe and Japan as well. So we had to align all the regulatory authorities around that design and we got there. So it’s a pretty great design I think for this program.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And standard endpoint, right? Percent reduction versus placebo at six months?

Jill Millney, CEO, Astria Therapeutics: Yes, at six months.

John Wallabin, Senior Analyst, Citizens Life Science Conference: How does that work when you’re dosing once?

Jill Millney, CEO, Astria Therapeutics: That is the endpoint. Yeah, and just to put that in perspective, the dose for the Q6 month regimen is six hundred milligrams. And that six hundred milligrams dose, you give it, you get to greater than 80% of steady state right away. And so that enables you to sort of look at that effect over that six months. But you’re right, those patients are getting a single dose.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And then a placebo, it’s three months, placebo injection, months? Exactly.

Jill Millney, CEO, Astria Therapeutics: Yes, that’s right because it’s a single placebo and that’s why this is a good trial for patients and I think the regulators saw that as well as you know to have to run two placebo controlled trials to support those regimens is not great for patients and so we really great for the regulators to have agreed to that as well.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Have you talked about the hierarchy if you’re looking at three and six months? Which one is your primary and how does that flow through?

Jill Millney, CEO, Astria Therapeutics: So the way we’ve done it is the endpoints in the trial are in, they’ll be assessed in a hierarchical order as individual arms compared to placebo.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Okay Dr.:

Jill Millney, CEO, Astria Therapeutics: So that’s how it is. There isn’t a hierarchy of arms. Each arm is individually compared to placebo.

John Wallabin, Senior Analyst, Citizens Life Science Conference: I see. And just given the effect size that should have enough alpha?

Jill Millney, CEO, Astria Therapeutics: Yeah, so the alpha is so point zero five divided by three to cover the three dose arms. But it’s this trial was designed to be very well powered of course to optimize the chances of success of all three of those arms.

John Wallabin, Senior Analyst, Citizens Life Science Conference: I can’t recall a phase three AGE study failing.

Jill Millney, CEO, Astria Therapeutics: Yeah.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Has it happened?

Jill Millney, CEO, Astria Therapeutics: Not that I can recall.

John Wallabin, Senior Analyst, Citizens Life Science Conference: So it just becomes how do you compare to the other agents either approved or in development?

Jill Millney, CEO, Astria Therapeutics: Yeah. And I yes. And so we’ve just seen, you know, obviously Tekxaro was one of the first mechanisms, well there were two others before that, but that sort of set the stage I think for the efficacy threshold in that eighty to ninety percent and we just saw Garidesmab and Ionis Donalodorsen report theirs in that range as well.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And we’ve been covering BioCryst forever. Their drug Orlodea, once daily oral drug, has seen tremendous uptake. They just raised guidance again and I think that’s to our previous comments about patients wanting to look for something more convenient. How do you think about any leeway you may have in your efficacy or tolerability profile for something that every six months is such a paramount difference between every two weeks? Or do you need to have that efficacy profile on par?

Like how do you think about that trade off?

Jill Millney, CEO, Astria Therapeutics: Yeah, I think so we have good confidence in both the Q3 month and the Q6 month to deliver that eighty percent to ninety percent efficacy range. But I agree with what you’re saying for some patients, you know, maybe the most severe patients or a patient going through a certain point in their life where we know stress induces these attacks. Maybe they need to be on a higher dose so might choose our Q3 month option to make sure that they’re getting delivered the best dose to meet them where they are in terms of their disease. But I think you’re right that I mean Orlodea has had a phenomenal launch and sustained growth for that product. I think that does speak to patients really want something that fits in their lifestyle.

And so for patients on Orlodayo, the equation of thinking about dosing with an injection every two weeks that’s painful, they choose Orlodayo.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Do you have any requirements from FDA from a safety perspective about like number of doses given because you’re dosing so infrequently in your clinical program?

Jill Millney, CEO, Astria Therapeutics: Yeah, so we’ll have to have a safety database as well and so the phase three the way it’s designed so we have our pivotal that’s that six month treatment period. All patients will have the ability to choose to go into extension along a long term trial following that. It’s called our Alpha Expanse. We’ll continue to collect data on safety of course in that Alpha Expanse. We’ll also continue to collect efficacy data as well And so all of that together will be part of the submission that ultimately we provide.

John Wallabin, Senior Analyst, Citizens Life Science Conference: When will you be able to submit your NDA following the primary endpoint? Will you need longer follow-up or will

Jill Millney, CEO, Astria Therapeutics: That’s not critical path right now. So yeah, and we haven’t given an exact time, but we’ll certainly update that as we get enrollment lockdown.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Yeah. If you guys give guidance for enrollment, you’ve given a data so we can back out to that. So just, you know, if we have data, what would you guys said I think first half?

Jill Millney, CEO, Astria Therapeutics: Early ’20 ’7.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Early ’20 ’7, so we back out and then just make sure you’re on track for that enrollment. Because it has to be competitive with drugs available and then also multiple clinical programs going on.

Jill Millney, CEO, Astria Therapeutics: For sure. And I will say we have a pretty exceptional team in terms of clinical operations, clinical development, and our patient advocacy and medical affairs. This is a team that has a whole lot of experience in rare disease phase threes. And so I think knows what the challenge is and is up for it. And so we certainly when we designed the strategy behind the phase three we took into account what other trials would be ongoing at the time.

I’ll say, you know, to point to the team’s exceptional success and excellence in executing, know, the phase one, b, two trial rolled in faster than we thought it would. In The US and Canada we originally thought we’re going to have to open sites in Europe to enroll that trial, but enrolled quicker than we can get sites opened up outside of The US. So that was a good sign. I think the other thing, know, we designed the phase three for patients. We designed it with input from physicians and patients to make it really as optimal as we could for the patient experience and quite frankly the sites and the physician experience as well.

And all that together is great, but I think one thing that we’re seeing is a lot of enthusiasm for nivenebart as well. And think the profile of Nivenabart is something that has been attractive to patients. And so that’s helping, I think, with enrollment.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And maybe last question on Nivenabart. Can you talk about the research you’ve done about potential uptake and the opportunity given every three and six month dosing and how that fits in versus other options out there.

Jill Millney, CEO, Astria Therapeutics: Yeah, so we’ve done market research and we’ve also seen market research done by some other external groups.

John Wallabin, Senior Analyst, Citizens Life Science Conference: Including us.

Jill Millney, CEO, Astria Therapeutics: Including you, yes. And I think it points to that both the every three month and the every six month appear to be real step changes in terms of how people think about treating this disease. And you know I think what we’ve seen is that market share from our market research and others will come not only from new patients that are just diagnosed with the disease but also from patients who are currently on a preventative but are very open to switching to something that fits in their lifestyle better with the efficacy profile that we think we can achieve with nivenabart. So we’re pretty optimistic about our potential to become that market leading product in the space.

John Wallabin, Senior Analyst, Citizens Life Science Conference: So nivenabart is what caught our attention. And then when we started looking at STARR310 as well, also I think a pretty compelling profile when we think about atopic dermatitis and the size of that market. But, you know, we dug in a little while back. We had phase three data for another OX40 agonist that didn’t look that great. Why is STARR three ten gonna be different?

Jill Millney, CEO, Astria Therapeutics: Yeah. I mean, we’re fortunate. This is a, you know, a mechanism in an area where actually learning from the programs ahead of us was really important. When we so we designed three ten in this program based on learnings from the Amgen program, from the Sanofi program where we thought taking those learnings and engineering an antibody that we thought addressed the potential liabilities of those programs, we could create something that could be best in class in the OX40 space and I think that’s what we have with STARR310.

John Wallabin, Senior Analyst, Citizens Life Science Conference: What’d you do?

Jill Millney, CEO, Astria Therapeutics: So with, as we think about roclotilimab, we have engineered STARR310 to, we hope avoid the safety tolerability issues associated with T cells killing. That roclotilimab was an antibody that was engineered to kill T cells and as a result you see fever and chills as one of the safety tolerability effects in the trials. And in a disease like atopic dermatitis that’s just not going to fly and I think what we believed with roclotilimab is they were going to leave efficacy on the table because they couldn’t dose high enough to drive efficacy to levels that you’d want to for a competitive profile in atopic dermatitis. By reducing or eliminating the T cell killing the ADCC in STARR310, our hope is that we can dose STAR310 to levels where we can really drive the efficacy to greater places, so open up that therapeutic window.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And what’s your duration, your target duration for STAR310?

Jill Millney, CEO, Astria Therapeutics: Yeah, so that’s another aspect of the program. We also engineered STARR310 for a long half life, so it’s also leveraged the YTE half life extension technology. Our hope with this program is we could dose as infrequently as every six months. And that’s an important aspect of the OX40 mechanism as well. Not only do we think we can address the symptoms of atopic dermatitis, but we think this mechanism, based on what we understand about it, we think can be disease modifying in atopic dermatitis.

And that’s one of the real excitements about this space.

John Wallabin, Senior Analyst, Citizens Life Science Conference: And you mentioned earlier you have a phase one ongoing, data 3Q, but healthy volunteers. Are we going to learn enough? What are we going to see?

Jill Millney, CEO, Astria Therapeutics: Yeah, so this phase 1a healthy volunteer trial is pretty important for our program in that we will see if what we engineered in it has really led to what we think could be a differentiated profile that could read on differentiated efficacy, safety, tolerability, and half life. And so what we know about the other programs, the roclotilimab program is in a healthy subject trial, greater than fifty percent of the subjects in their trial had fever, likely because of the T cell killing. So we’ll be looking very closely at safe tolerability across our dose range. Half life will be important for us to establish that we do have an antibody that could be dosed infrequently because we think those two things combined can really lead to our ability to drive efficacy.

John Wallabin, Senior Analyst, Citizens Life Science Conference: So if we see a reduced incidence of pyrexia chills fever, that should give us some inkling that you’re going have a differentiated profile. It could be really keep it simple stupid. If we see that we’re on the right track?

Jill Millney, CEO, Astria Therapeutics: Yes. You know, in star three ten we’ll also be looking at things like receptor occupancy knowing we’re we’re covering the receptor the way we we want to. Yes. So that’s gonna be

John Wallabin, Senior Analyst, Citizens Life Science Conference: Counting fevers is easier than triangulating potency, EC 50, EC90. So, okay. And then can you remind us in the last little bit of time your current cash position, you know, runway including Callus that we talked about, but maybe just putting a button on things to look forward to over the next twelve, eighteen months?

Jill Millney, CEO, Astria Therapeutics: Yeah. So we’re in a good strong cash position, cash into mid twenty twenty seven. So importantly, through the key milestones for the nivenabart phase three program. So we’ll get through our top line data with that program. That’s really important and certainly our priority for the program.

Upcoming milestones. So we have the Alpha Solar long term extension data from the Novenebar program that will read out mid year. And that will be data on safety, tolerability, and efficacy of Novenebart following every three month dosing or every six month dosing. And so we have patients who now have been on Novenebart for more than eighteen months. So we’ll have that data midyear.

And then for SAR-three ten, the major milestone is the phase 1a healthy subject data in Q3.

John Wallabin, Senior Analyst, Citizens Life Science Conference: So stuff in the next six months even that we’ll be looking forward to. So very exciting times. Jill, thanks again for joining us, and we look forward to catching up with you guys.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.